不断发展的免疫检查点抑制剂的体位学和用药：皮下制剂

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2024-04-06 DOI:10.1016/j.trecan.2024.03.006

Matthew J. Hadfield, David J. Benjamin, Jonathan Krell, Jeremy Warner, Mark P. Lythgoe

{"title":"不断发展的免疫检查点抑制剂的体位学和用药：皮下制剂","authors":"Matthew J. Hadfield, David J. Benjamin, Jonathan Krell, Jeremy Warner, Mark P. Lythgoe","doi":"10.1016/j.trecan.2024.03.006","DOIUrl":null,"url":null,"abstract":"<p>Immune checkpoint inhibitors (ICIs) have transformed cancer care. Recently, atezolizumab gained its first global approval in a subcutaneous (SC) formulation by the UK medicines regulator, being notable as the first time an FDA- and/or European Medicines Agency (EMA)-approved ICI has been licensed via this administration route. Here, we discuss this approval, other SC ICIs in development, and the benefits and challenges of this administration route, including potential implications for patient care.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"45 1","pages":""},"PeriodicalIF":14.3000,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations\",\"authors\":\"Matthew J. Hadfield, David J. Benjamin, Jonathan Krell, Jeremy Warner, Mark P. Lythgoe\",\"doi\":\"10.1016/j.trecan.2024.03.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Immune checkpoint inhibitors (ICIs) have transformed cancer care. Recently, atezolizumab gained its first global approval in a subcutaneous (SC) formulation by the UK medicines regulator, being notable as the first time an FDA- and/or European Medicines Agency (EMA)-approved ICI has been licensed via this administration route. Here, we discuss this approval, other SC ICIs in development, and the benefits and challenges of this administration route, including potential implications for patient care.</p>\",\"PeriodicalId\":23336,\"journal\":{\"name\":\"Trends in cancer\",\"volume\":\"45 1\",\"pages\":\"\"},\"PeriodicalIF\":14.3000,\"publicationDate\":\"2024-04-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.trecan.2024.03.006\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2024.03.006","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

免疫检查点抑制剂（ICIs）改变了癌症治疗。最近，atezolizumab 的皮下 (SC) 制剂首次获得英国药品监管机构的全球批准，这也是美国食品药品管理局和/或欧洲药品管理局 (EMA) 批准的 ICI 首次通过这种给药途径获得许可。在此，我们将讨论这一批准、其他正在开发中的皮下 ICI 以及这种给药途径的优势和挑战，包括对患者护理的潜在影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations

Immune checkpoint inhibitors (ICIs) have transformed cancer care. Recently, atezolizumab gained its first global approval in a subcutaneous (SC) formulation by the UK medicines regulator, being notable as the first time an FDA- and/or European Medicines Agency (EMA)-approved ICI has been licensed via this administration route. Here, we discuss this approval, other SC ICIs in development, and the benefits and challenges of this administration route, including potential implications for patient care.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.